You are here: Home » PTI Stories » National » News
Business Standard

AstraZeneca gets 6-mth extension to sell Meronem in India

Press Trust of India  |  New Delhi 

has got an extension from its parent firm AstraZeneca to sell anti-bacterial drug Meronem in for the next six months.

"Ltd has received on December 01, 2016 a notice to extend the date of distribution arrangements for Meronem up to July 31, 2017, during which time the parties shall continue to act in accordance with the terms and conditions of the agreement,"the company said in a filing.



It further added: "The extension is due to the delay in the divestment of AstraZeneca's global rights to Meronem."

Meronem is anti-bacterial used for the treatment of serious infections in hospitalised patients.

In August this year, had said that it will stop selling anti-bacterial drug Meronem in following a global deal by its parent AstraZeneca to sell its small molecule antibiotics business to Inc.

The company had received a notice of termination from AstraZeneca conveying its decision for termination of distribution arrangements for Meronem in India.

The product is currently one of the company's principal products which generated 18 per cent total turnover of the firm in fiscal ended March 31, 2016.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

AstraZeneca gets 6-mth extension to sell Meronem in India

AstraZeneca Pharma India has got an extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India for the next six months. "AstraZeneca Pharma India Ltd has received on December 01, 2016 a notice to extend the date of distribution arrangements for Meronem up to July 31, 2017, during which time the parties shall continue to act in accordance with the terms and conditions of the agreement,"the company said in a BSE filing. It further added: "The extension is due to the delay in the divestment of AstraZeneca's global rights to Meronem." Meronem is anti-bacterial used for the treatment of serious infections in hospitalised patients. In August this year, AstraZeneca Pharma India had said that it will stop selling anti-bacterial drug Meronem in India following a global deal by its parent AstraZeneca UK to sell its small molecule antibiotics business to Pfizer Inc. The company had received a notice of termination from AstraZeneca UK conveying its decision ... has got an extension from its parent firm AstraZeneca to sell anti-bacterial drug Meronem in for the next six months.

"Ltd has received on December 01, 2016 a notice to extend the date of distribution arrangements for Meronem up to July 31, 2017, during which time the parties shall continue to act in accordance with the terms and conditions of the agreement,"the company said in a filing.

It further added: "The extension is due to the delay in the divestment of AstraZeneca's global rights to Meronem."

Meronem is anti-bacterial used for the treatment of serious infections in hospitalised patients.

In August this year, had said that it will stop selling anti-bacterial drug Meronem in following a global deal by its parent AstraZeneca to sell its small molecule antibiotics business to Inc.

The company had received a notice of termination from AstraZeneca conveying its decision for termination of distribution arrangements for Meronem in India.

The product is currently one of the company's principal products which generated 18 per cent total turnover of the firm in fiscal ended March 31, 2016.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

AstraZeneca gets 6-mth extension to sell Meronem in India

has got an extension from its parent firm AstraZeneca to sell anti-bacterial drug Meronem in for the next six months.

"Ltd has received on December 01, 2016 a notice to extend the date of distribution arrangements for Meronem up to July 31, 2017, during which time the parties shall continue to act in accordance with the terms and conditions of the agreement,"the company said in a filing.

It further added: "The extension is due to the delay in the divestment of AstraZeneca's global rights to Meronem."

Meronem is anti-bacterial used for the treatment of serious infections in hospitalised patients.

In August this year, had said that it will stop selling anti-bacterial drug Meronem in following a global deal by its parent AstraZeneca to sell its small molecule antibiotics business to Inc.

The company had received a notice of termination from AstraZeneca conveying its decision for termination of distribution arrangements for Meronem in India.

The product is currently one of the company's principal products which generated 18 per cent total turnover of the firm in fiscal ended March 31, 2016.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard